SCHEMBL6007384

SCHEMBL6007384

CCN([C]=O)NC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 8/20 0.43
CTSL P07711 3/20 0.43
CTSB P07858 3/20 0.43
CTSD P07339 1/20 0.43
CA1 P00915 2/20 0.40
CA7 P43166 2/20 0.40
CA12 O43570 2/20 0.40
CA14 Q9ULX7 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
AKT1 P31749 2/20 0.37
APLNR P35414 1/20 0.37
CTSK P43235 6/20 0.36
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
CA2 P00918 2/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1193474 0.86 CA1 (0.49) CTSSCTSLCTSBCTSDCA1
SCHEMBL6850051 0.80 CA12 (0.41) CTSSCTSLCTSBCTSDCA1
SCHEMBL6006527 0.80 MAPT (0.35) MAPT
SCHEMBL13197738 0.76 CA1 (0.44) CTSSCTSLCTSBCTSDCA1
SCHEMBL10199933 0.75 CA1 (0.43) CTSSCTSLCTSBCTSDCA1
SCHEMBL6750482 0.74 CA1 (0.40) CTSSCTSLCTSBCTSDCA1
SCHEMBL24959639 0.73 CA1 (0.39) CTSSCTSLCTSBCTSDCA1
SCHEMBL2788302 0.72 AKT1 (0.44) CTSSCTSLCTSBCTSDCA1
SCHEMBL2942682 0.70 AKT1 (0.43) CTSSCTSLCTSBCTSDCA1
SCHEMBL8568535 0.70 APLNR (0.42) CA1CA7CA12CA14TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 CTSS 4001/4885CTSL 4707/4885CTSB 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.